» Articles » PMID: 35402303

Hepatitis C Virus Infection Cycle-Specific MicroRNA Profiling Reveals Stage-Specific MiR-4423-3p Targets RIG-I to Facilitate Infection

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatitis C virus (HCV) infection is one of the main causes of chronic liver diseases, the disorders of which involve multiple pathological processes and elements including host factors such as non-coding small RNAs. Although several genes have been reported to be correlated with HCV infection, the potential regulatory network has not been deciphered clearly. By small RNA sequencing, we clarified the expression profile of microRNAs (miRNAs) in HCV-infected Huh7 and Huh7.5.1 cells and identified 6 dysregulated miRNAs with the same expression trend and 32 dysregulated miRNAs with different expression trends during different stages of HCV life cycle. By looking into each infection stage, we found that 6 miRNAs were entry stage specific, 4 miRNAs were replication stage specific, and 1 miRNA was related to the transmission stage. Moreover, due to the fact that Huh7.5.1 cells have a retinoic acid-inducible gene 1 (RIG-I) mutation which causes reduced production of interferons (IFNs), we here focused on the miRNAs of different trends to decipher the RIG-I/IFN specific miRNAs. Among them, miR-4423-3p showed a significant promotive effect on HCV infection by suppressing RIG-I/IFN pathway through direct binding to RIG-I mRNA. Together, the results displayed novel insights into the miRNA regulatory networks in HCV infection and progression, thus providing a prosperous perspective into the establishment of novel therapeutic and diagnostic targets of the disease.

Citing Articles

Host Factors Modulate Virus-Induced IFN Production via Pattern Recognition Receptors.

Wang J, Dong Y, Zheng X, Ma H, Huang M, Fu D J Inflamm Res. 2024; 17:3737-3752.

PMID: 38882189 PMC: 11180453. DOI: 10.2147/JIR.S455035.


MicroRNAs in the Regulation of RIG-I-like Receptor Signaling Pathway: Possible Strategy for Viral Infection and Cancer.

Chen D, Ji Q, Liu J, Cheng F, Zheng J, Ma Y Biomolecules. 2023; 13(9).

PMID: 37759744 PMC: 10526236. DOI: 10.3390/biom13091344.

References
1.
Nahand J, Bokharaei-Salim F, Salmaninejad A, Nesaei A, Mohajeri F, Moshtzan A . microRNAs: Key players in virus-associated hepatocellular carcinoma. J Cell Physiol. 2018; 234(8):12188-12225. DOI: 10.1002/jcp.27956. View

2.
Lazarus J, Picchio C, Guy D, Aleman S, James C, Nava F . Hepatitis C standards of care: A review of good practices since the advent of direct-acting antiviral therapy. Clin Res Hepatol Gastroenterol. 2021; 45(2):101564. DOI: 10.1016/j.clinre.2020.11.001. View

3.
Suryaprasad A, White J, Xu F, Eichler B, Hamilton J, Patel A . Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis. 2014; 59(10):1411-9. DOI: 10.1093/cid/ciu643. View

4.
Gao L, Nie Q, Zhao X . Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C. Int J Gen Med. 2021; 14:289-301. PMC: 7850569. DOI: 10.2147/IJGM.S283910. View

5.
Peng X, Li Y, Walters K, Rosenzweig E, Lederer S, Aicher L . Computational identification of hepatitis C virus associated microRNA-mRNA regulatory modules in human livers. BMC Genomics. 2009; 10:373. PMC: 2907698. DOI: 10.1186/1471-2164-10-373. View